Market open
Delcath Systems/$DCTH
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Delcath Systems
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Ticker
$DCTH
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
76
Website
Delcath Systems Metrics
BasicAdvanced
$500M
-
-$1.30
0.87
-
Price and volume
Market cap
$500M
Beta
0.87
52-week high
$16.44
52-week low
$3.70
Average daily volume
453K
Financial strength
Current ratio
1.338
Quick ratio
0.974
Long term debt to equity
11.236
Total debt to equity
35.818
Interest coverage (TTM)
-172.60%
Management effectiveness
Return on assets (TTM)
-42.19%
Return on equity (TTM)
-174.71%
Valuation
Price to revenue (TTM)
18.137
Price to book
51.16
Price to tangible book (TTM)
51.16
Price to free cash flow (TTM)
-15.674
Growth
Revenue change (TTM)
945.91%
Earnings per share change (TTM)
-62.57%
3-year revenue growth (CAGR)
126.30%
3-year earnings per share growth (CAGR)
-32.62%
What the Analysts think about Delcath Systems
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Delcath Systems stock.
Delcath Systems Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Delcath Systems Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Delcath Systems News
AllArticlesVideos
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·4 weeks ago
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer
Business Wire·2 months ago
Delcath Begins Platform Expansion With Two Phase 2 Trials
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Delcath Systems stock?
Delcath Systems (DCTH) has a market cap of $500M as of January 30, 2025.
What is the P/E ratio for Delcath Systems stock?
The price to earnings (P/E) ratio for Delcath Systems (DCTH) stock is 0 as of January 30, 2025.
Does Delcath Systems stock pay dividends?
No, Delcath Systems (DCTH) stock does not pay dividends to its shareholders as of January 30, 2025.
When is the next Delcath Systems dividend payment date?
Delcath Systems (DCTH) stock does not pay dividends to its shareholders.
What is the beta indicator for Delcath Systems?
Delcath Systems (DCTH) has a beta rating of 0.87. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.